Ulcerative colitis remission status after induction with mesalazine predicts maintenance outcomes: The MOMENTUM trial

Journal of Crohn's and Colitis

Volumn 10, Issue 8, 2016, Pages 925-933

  Rubin, David T ^a   Bradette, Marc ^b,c   Gabalec, Libor ^c   Dobru, Daniela ^c,d   Márquez, Juan ^c,e   Inglis, Susi ^f   Magee, Elizabeth ^g   Solomon, Dory ^g   D'Haens, Geert ^c,h   Baert, Filip ^c   D'Heygere, Francois ^c   Marshall, John ^c   Ostro, Michael ^c   Pare, Pierre ^c   Feris, Jacobo ^c   Juliao, Fabian ^c   Orozco, Alejandro ^c   Benes, Marek ^c   Compel, Vladimir ^c   Douda, Ladislav ^c   Hejcman, Jan ^c   Kozeluhova, Jana ^c   Lukas, Milan ^c   Nosek, Vladimir ^c   Tichy, Michal ^c   Vanasek, Tomas ^c   Bourreille, Arnaud ^c   Zerbib, Frank ^c   Kucharzik, Torsten ^c   Grenda, Andor ^c   Gurzo, Zoltan ^c   Pecsi, Gyula ^c   Szaloki, Tibor ^c   Banerjee, Rupa ^c   Bhandarkar, Prashant ^c   Chandra, Abhijit ^c   Goswami, Bhabadev ^c   Kalla, Mukesh ^c   Kolte, Sanjay ^c   Mehta, Rupesh Bhaidas ^c   Krishna, Palakurthi Murali ^c   Nijhawan, Sandeep ^c   Shenoy, K T ^c   Sood, Ajit ^c   Vishwanath Tantry, B ^c   Thorat, Vinay ^c   Mulcahy, Hugh ^c   O'Morain, Colm ^c   Patchett, Stephen ^c   Hanczewski, Marcin ^c   Horynski, Marek ^c   Petryka, Robert ^c   Piotrowski, Wojciech ^c   Rozciecha, Jerzy ^c   Skoczylas, Marek ^c   Andronescu, Dan ^c   Banciu, Christian ^c   Gheorghe, Liliana ^c   Goldis, Adrian ^c   Stoica, Victor ^c   Aboo, Nazimbuddin ^c   Bester, Frederick ^c   Moola, Suleman ^c   Prins, Maarten ^c   van Rensburg, Christo ^c   Wright, John ^c   Gisbert, Javier P ^c   Travis, Simon ^c   Aguilar, Humberto ^c   Altman, Richard ^c   Bhandari, Raj ^c   Catinis, George ^c   Chintalapani, Sreenivas ^c   Desautels, Steven ^c   Emin Donat, M ^c   Epstein, Michael ^c   Gaddam, Syam ^c   Geenen, Daniel ^c   Ginzburg, Lev ^c   Goldberg, Lawrence ^c   Homoky, Douglas ^c   Jamal, M Mazen ^c   Kreines, Michael ^c   LeVine, Michael ^c   Loftus, Edward ^c   Minton, Stephen ^c   Nagrani, Mark ^c   Narayen, Vijay ^c   Pratha, Vijayalakshmi ^c   Randall, Charles ^c   Rubin, David ^c   Winkle, Peter ^c   Wolf, Douglas ^c   Zakko, Salam ^c   more..

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b Université Laval   (Canada)

^c Department of Internal Medicine ^*  (United States)

^d UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e Clinica Las Americas   (Colombia)

^f Shire Pharmaceuticals   (United Kingdom)

^g SHIRE   (United States)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

5 aminosalicylic acid 5 ASA ; Inflammatory bowel disease; MOMENTUM

Indexed keywords

MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; ANEMIA; APHTHOUS STOMATITIS; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOSCOPY; FECES; FEMALE; FEVER; HEADACHE; HEALING; HERPES ZOSTER; HUMAN; HYPERTENSION; INFLUENZA; LUNG INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSAL HEALING; MULTICENTER STUDY; OPEN STUDY; OSTEOARTHRITIS; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RECTUM HEMORRHAGE; RELAPSE; REMISSION; RHINOPHARYNGITIS; SINUSITIS; TOOTH PAIN; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UVEITIS; ADOLESCENT; AGED; CLINICAL TRIAL; COLITIS, ULCERATIVE; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MALE; MESALAMINE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84995664539     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ECCO-JCC/JJW049     Document Type: Article

References (18)

1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-94
2. Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 2008;14:554-65
3. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-23
4. Naganuma M, Sakuraba A, Hibi T. Ulcerative colitis: prevention of relapse. Expert Rev Gastroenterol Hepatol 2013;7:341-51
5. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006;23:577-85
6. Meucci G, Fasoli R, Saibeni S, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis 2012;18:1006-10
7. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201
8. Travis SP, Stange EF, Lemann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008;2:24-62
9. LIALDA® [mesalamine] delayed-release tablets, for oral use [package insert]. Wayne, PA: Shire US Inc.; 2014
10. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007;132:66-75
11. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once-or twicedaily MMX mesalamine [SPD476] for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007;5:95-102
12. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once-or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008;57:893-902
13. Kane S, Katz S, Jamal MM, et al. Strategies in maintenance for patients receiving long-term therapy [SIMPLE]: a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. Inflamm Bowel Dis 2012;18:1026-33
14. D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P. Once-daily MMX® mesalamine for endoscopic maintenance of remission of ulcerative colitis. Am J Gastroenterol 2012;107:1064-77
15. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis 2009;15:1-8
16. Takeshima F, Matsumura M, Makiyama K, et al. Efficacy of long-term 4.0 g/day mesalazine [Pentasa] for maintenance therapy in ulcerative colitis. Med Sci Monit 2014;20:1314-8
17. Khan N, Abbas AM, Koleva YN, Bazzano LA. Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose. Inflamm Bowel Dis 2013;19:1123-9
18. Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007;26:205-15